SOPHIA ANTIPOLIS, France – November 04, 2024 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Circular RNAs present advantages over conventional therapeutics mRNAs Circular RNA (circRNA) is a unique type of single-stranded[…]
SOPHIA ANTIPOLIS, France – October 09, 2024 │ Amidst the rapidly evolving landscape of medical biotechnology, especially in the therapeutic RNA sector, groundbreaking advances continue to reshape the field. The latest release of our Therapeutic mRNA patent monitor delivers comprehensive insights, underscoring a notable acceleration in intellectual property developments, pushing the boundaries of RNA-based treatments[…]
SOPHIA ANTIPOLIS, France – September 03, 2024 │ The last quarterly report for the 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. Monkeypox virus, a new threat? Mpox, also known as monkeypox, is a viral disease caused by the[…]
SOPHIA ANTIPOLIS, France – September 03, 2024 │ The quarterly report for the Q2 2024 Therapeutic mRNA patent monitor is now available! This report covers all aspects of mRNA design, delivery, manufacturing, storing, mRNA-based vaccines, and mRNA-based therapeutics. What’s new this quarter? Q2 2024 patenting activity maintains steady pace with notable new granted patents in[…]